High rates of multidrug resistance among uropathogenic Escherichia coli in children and analyses of ESBL producers from Nepal
Tóm tắt
Từ khóa
Tài liệu tham khảo
Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev. 2005;18(2):417–22.
Desai DJ, Gilbert B, McBride CA. Paediatric urinary tract infections: Diagnosis and treatment. Aust Fam Physician. 2016;45(8):558–63.
Robinson JL, Le Saux N. Management of urinary tract infections in children in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther. 2016;14(9):809–16.
Hay AD, Sterne JA, Hood K, Little P, Delaney B, Hollingworth W, Wootton M, Howe R, MacGowan A, Lawton M, et al. Improving the Diagnosis and Treatment of Urinary Tract Infection in Young Children in Primary Care: Results from the DUTY Prospective Diagnostic Cohort Study. Ann Fam Med. 2016;14(4):325–36.
Hanna-Wakim RH, Ghanem ST, El Helou MW, Khafaja SA, Shaker RA, Hassan SA, Saad RK, Hedari CP, Khinkarly RW, Hajar FM, et al. Epidemiology and characteristics of urinary tract infections in children and adolescents. Front Cell Infect Microbiol. 2015;5:45.
Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657–86.
Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med. 2012;27(2):128–42.
Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14(4):933–51. table of contents.
Sedighi I, Arabestani MR, Rahimbakhsh A, Karimitabar Z, Alikhani MY. Dissemination of extended-spectrum beta-lactamases and quinolone resistance genes among clinical isolates of uropathogenic escherichia coli in children. Jundishapur J Microbiol. 2015;8(7):e19184.
Uyar Aksu N, Ekinci Z, Dundar D, Baydemir C. Childhood urinary tract infections caused by ESBL-producing bacteria: Risk factors and empiric therapy. Pediatr Int. 2016. 0.1111/ped.13112. (Epub ahead of print).
Rai GK, Upreti HC, Rai SK, Shah KP, Shrestha RM. Causative agents of urinary tract infections in children and their antibiotic sensitivity pattern: a hospital based study. Nepal Med Coll J. 2008;10(2):86–90.
Singh SD, Madhup SK. Clinical profile and antibiotics sensitivity in childhood urinary tract infection at Dhulikhel Hospital. KUMJ. 2013;11(44):319–24.
Flokas ME, Detsis M, Alevizakos M, Mylonakis E. Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: A systematic review and meta-analysis. J Infect. 2016;73(6):547–57.
Sharma S, Kaur N, Malhotra S, Madan P, Ahmad W, Hans C. Serotyping and antimicrobial susceptibility pattern of escherichia coli isolates from urinary tract infections in pediatric population in a tertiary care hospital. J Pathog. 2016;2016:2548517.
Isenberg HD. Clinical Microbiology Procedures Handbook. 2nd edition. Washington DC: ASM press; 2004.
Performance Standards for Antimicrobial Disk Susceptibility Tests.2012. Clinical and Laboratory Standards Institute. 2012, M02-A11 (Approved Standard—Eleventh Edition).
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.
Shah Samin Ullah AAG. Islam Rehman Gohar: etiology and antibiotic resistance pattern of community-acquired urinary tract infections in children. KJMS. 2015;8(3):428.
Moore CE, Sona S, Poda S, Putchhat H, Kumar V, Sopheary S, Stoesser N, Bousfield R, Day N, Parry CM. Antimicrobial susceptibility of uropathogens isolated from Cambodian children. Paediatr Int Child Health. 2016:1–5. [Epub ahead of print].
Masud MR, Afroz H, Fakruddin M. Prevalence of extended-spectrum beta-lactamase positive bacteria in radiologically positive urinary tract infection. Springer Plus. 2014;3:216.
Pourakbari B, Ferdosian F, Mahmoudi S, Teymuri M, Sabouni F, Heydari H, Ashtiani MT, Mamishi S. Increase resistant rates and ESBL production between E. coli isolates causing urinary tract infection in young patients from Iran. Braz J Microbiol. 2012;43(2):766–9.
Shettigar SCG, Roche R, Nayak N, Anitha KB, Soans S. Bacteriological profile, antibiotic sensitivity pattern, and detection of extended-spectrum β-lactamase in the isolates of urinary tract infection from children. J Child Health. 2016;3(1):5.
Rezai MS, Salehifar E, Rafiei A, Langaee T: Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran. 2015, 2015:309478
Kizilca O, Siraneci R, Yilmaz A, Hatipoglu N, Ozturk E, Kiyak A, Ozkok D. Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children. Pediatr Int. 2012;54(6):858–62.
Balaji Chinnasami SS. Kanimozhi Sadasivam, Sekar Pasupathy Pathogens Causing Urinary Tract Infection in Children and their in vitro Susceptibility to Antimicrobial Agents- A Hospital Based Study. Biomed Pharmacol J. 2016;9(1):7.
Wu CT, Lee HY, Chen CL, Tuan PL, Chiu CH. High prevalence and antimicrobial resistance of urinary tract infection isolates in febrile young children without localizing signs in Taiwan. J Microbiol Immunol Infect=Wei mian yu gan ran za zhi. 2016;49(2):243–8.
Degnan LA, Milstone AM, Diener-West M, Lee CK. Extended-spectrum beta-lactamase bacteria from urine isolates in children. J Pediatr Pharmacol Ther. 2015;20(5):373–7.
Han SB, Lee SC, Lee SY, Jeong DC, Kang JH. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. BMC Infect Dis. 2015;15:414.
Dotis J, Printza N, Marneri A, Gidaris D, Papachristou F. Urinary tract infections caused by extended-spectrum betalactamase-producing bacteria in children: a matched casecontrol study. Turk J Pediatr. 2013;55(6):571–4.
Lee B, Kang SY, Kang HM, Yang NR, Kang HG, Ha IS, Cheong HI, Lee HJ, Choi EH. Outcome of antimicrobial therapy of pediatric urinary tract infections caused by extended-spectrum beta-lactamase-producing enterobacteriaceae. Infect Chemother. 2013;45(4):415–21.
Sharma A, Shrestha S, Upadhyay S, Rijal P. Clinical and bacteriological profile of urinary tract infection in children at Nepal Medical College Teaching Hospital. Nepal Med Coll J. 2011;13(1):24–6.
Mirsoleymani SR, Salimi M, Shareghi Brojeni M, Ranjbar M, Mehtarpoor M. Bacterial pathogens and antimicrobial resistance patterns in pediatric urinary tract infections: a four-year surveillance study (2009-2012). Int J Pediatr. 2014;2014:126142.
Stultz JS, Doern CD, Godbout E. Antibiotic resistance in pediatric urinary tract infections. Curr Infect Dis Rep. 2016;18(12):40.
Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis. 2006;42 Suppl 4:S164–172.
Dalgic N, Sancar M, Bayraktar B, Dincer E, Pelit S. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria in children. Scand J Infect Dis. 2011;43(5):339–43.
Park SH, Choi SM, Chang YK, Lee DG, Cho SY, Lee HJ, Choi JH, Yoo JH. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother. 2014;69(10):2848–56.
Asakura T, Ikeda M, Nakamura A, Kodera S. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis. 2014;29:91–5.
Tasbakan MI, Pullukcu H, Sipahi OR, Yamazhan T, Ulusoy S. Nitrofurantoin in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infection. Int J Antimicrob Agents. 2012;40(6):554–6.
Veve MP, Wagner JL, Kenney RM, Grunwald JL, Davis SL. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infections. Int J Antimicrob Agents. 2016;48(1):56–60.
Lepeule R, Ruppe E, Le P, Massias L, Chau F, Nucci A, Lefort A, Fantin B. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum beta-lactamase. Antimicrob Agents Chemother. 2012;56(3):1376–81.
Ansari S, Nepal HP, Gautam R, Shrestha S, Neopane P, Gurung G, Chapagain ML. Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal. Antimicrob Resist Infect Control. 2015;4:15.